Topic 4: Future Directions & Emerging Technologies-Biomarkers in Lung Cancer Screening (Non Imaging)

Biomarkers in Lung Cancer Screening (Non Imaging)

Video Transcription

Video Summary

The speaker discusses the importance of molecular biomarkers in lung cancer screening, highlighting that only a quarter of lung cancers in the U.S. are diagnosed early despite ongoing screenings. Challenges include low uptake, adherence, and the balance of screening benefits versus harms. Biomarkers undergo several developmental phases: discovery, analytical validation, clinical validation, and clinical utility, each with specific aims. Examples of ongoing studies show promising biomarkers that may enhance current lung cancer screening methods. Multi-cancer early detection tests could potentially contribute, but more development is needed for significant impact.

Asset Subtitle

Peter Mazzone

Keywords

molecular biomarkers

lung cancer screening

early detection

clinical validation

multi-cancer tests